Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System.
Rev Saude Publica
; 43 Suppl 1: 62-9, 2009 Aug.
Article
en En
| MEDLINE
| ID: mdl-19669066
OBJECTIVE: To assess the cost-utility of first and second-generation antipsychotics for treatment of schizophrenia. METHODS: A five-year Markov model was constructed based on a survey of the records of patients seen in 2006 at a psychosocial care center in the municipality of Florianopolis, Southern Brazil. Costs were evaluated from the perspective of the Sistema Unico de Saúde (SUS - Unified Healthcare System). Utility was measured in quality-adjusted life years obtained in the literature. RESULTS: The Markov model indicated risperidone and haloperidol utilization before olanzapine as the most cost-effective alternatives. CONCLUSIONS: Antipsychotic agents haloperidol and risperidone are more cost-effective than olanzapine. Strategies prioritizing the use of antipsychotics with better cost-effectiveness could optimize resource allocation without necessarily compromising the health of patients treated through the Sistema Unico de Saúde.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Esquizofrenia
/
Antipsicóticos
/
Benzodiazepinas
/
Costos de los Medicamentos
/
Risperidona
/
Haloperidol
Tipo de estudio:
Evaluation_studies
/
Health_economic_evaluation
Aspecto:
Patient_preference
Límite:
Humans
País/Región como asunto:
America do sul
/
Brasil
Idioma:
En
Revista:
Rev Saude Publica
Año:
2009
Tipo del documento:
Article
País de afiliación:
Brasil
Pais de publicación:
Brasil